TAKTIC: ipatasertib, endocrine therapy and CDK4/6i for patients with HR+/HER2- mBC

postMONARCHE: abemaciclib + fulvestrant in HR+/HER2- MBC following CDK4/6i & endocrine therapyПодробнее

CDK4/6 Inhibitors & Endocrine Therapy: Selecting a RegimenПодробнее

HR+ mBC: Treatment After Progression on CDK4/6 InhibitionПодробнее

CDK4/6 Inhibitors & Endocrine Therapy in Breast CancerПодробнее

CDK4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancerПодробнее

What's New for the Patient With ER+/HER2- MBC Progressing on CDK 4/6 Inhibitor Therapy? Expert Pe...Подробнее

Remaining questions on the use of frontline CDK4/6 inhibitors + endocrine therapyПодробнее

Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancerПодробнее

Unmet needs and CDK4/6 inhibitors in HR+/HER2- early breast cancerПодробнее

Impact of metastases-directed radiation therapy on CDK4/6 inhibitors treatment for mBCПодробнее

1L use of CDK4/6i + ET shows no clinically meaningful PFS compared to 2L use in HR+, HER2- ABCПодробнее

Dr. Tolaney on Remaining Questions With CDK4/6 Inhibitors in HR+/HER2- Breast CancerПодробнее

The use of frontline CDK4/6 inhibitors + endocrine therapy in metastatic breast cancerПодробнее

HR+ mBC: Factors in Selecting CDK4/6 InhibitionsПодробнее

CDK4/6 Inhibitors & Endocrine Therapy: Treatment ResistanceПодробнее

CDK4/6 inhibitors in early stage HR+/HER2- diseaseПодробнее

Questioning CDK4/6 Inhibitor Cross-Resistance in HR+ mBCПодробнее

Overcoming resistance to CDK4/6 inhibitors in ER+ breast cancer via ctDNAПодробнее

CDK 4/6 Inhibitors for Patients with Recurrent ER+/HER2- Breast Cancer: 2023 Best of BreastПодробнее